Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cross Country Healthcare (CCRN) Depreciation & Amortization - Total (2016)

Cross Country Healthcare's Depreciation & Amortization - Total history spans 7 years, with the latest figure at $1.1 million for Q4 2016.

  • For Q4 2016, Depreciation & Amortization - Total rose 16.25% year-over-year to $1.1 million; the TTM value through Sep 2017 reached $1.1 million, down 72.36%, while the annual FY2016 figure was $4.2 million, 8.09% up from the prior year.
  • Depreciation & Amortization - Total reached $1.1 million in Q4 2016 per CCRN's latest filing, up from $995000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $1.4 million in Q1 2012 to a low of $817000.0 in Q2 2014.
  • Average Depreciation & Amortization - Total over 5 years is $1.0 million, with a median of $1.0 million recorded in 2014.
  • The largest YoY upside for Depreciation & Amortization - Total was 43.39% in 2012 against a maximum downside of 33.14% in 2012.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $1.1 million in 2012, then dropped by 15.63% to $934000.0 in 2013, then increased by 14.56% to $1.1 million in 2014, then dropped by 10.84% to $954000.0 in 2015, then grew by 16.25% to $1.1 million in 2016.
  • Per Business Quant, the three most recent readings for CCRN's Depreciation & Amortization - Total are $1.1 million (Q4 2016), $995000.0 (Q3 2016), and $1.1 million (Q2 2016).